Autres langues CSPC Pharmaceutical Group Limited

Actions

1093

HK1093012172

Produits pharmaceutiques

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:24 28/07/2026			Varia. 5j.	Varia. 1 janv.
8,490 ^HKD	+2,29 %		-0,12 %	+0,71 %

05:03	Le traitement de CSPC Pharma contre la dépression atteint son critère d'évaluation principal en phase 3	MT
04:35	CSPC Pharma : la demande de mise sur le marché du Sirolimus acceptée en Chine	MT

Autres langues

05:03	CSPC Pharma's Depression Drug Meets Primary Endpoint in Phase 3 Trial
04:35	CSPC Pharma's Sirolimus Drug Application Accepted in China
27/07	CSPC Pharmaceutical Group Limited Announces Phase III Clinical Trial Results For Ammoxetine Hydrochloride Enteric-Coated Tablets For Depression
27/07	CSPC Pharmaceutical Group Limited Announces Acceptance Of New Drug Application For Sirolimus For Injection (Albumin-Bound) By NMPA
27/07	CSPC Pharmaceutical Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2026D Stable Sales Growth
24/07	CSPC Pharmaceutical Group Limited Announces Marketing Approval For Paliperidone Palmitate Injection
22/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial of Sys6026 Injection for HPV Type 16 or 18 Related Cervical High Grade Squamous Intraepithelial Lesion in China
17/07	CSPC Pharmaceutical Group Limited Announces New Drug Application for Trastuzumab Envedotin Injection Accepted by Nmpa
17/07	CSPC Pharma's Application for Breast Cancer Drug Candidate Accepted in China
16/07	CSPC Pharma Begins Two Drug Trials in China
15/07	CSPC Pharma's Breast Cancer Drug Combination Granted China Breakthrough Designation
14/07	CSPC Pharmaceutical Group Limited Announces Docetaxel for Injection (Albumin-Bound) and Anbenitamab Receives Breakthrough Therapy Designation in China for First-Line Treatment of Advanced HER2-Positive Breast Cancer Co-Developed by Shanghai JMT-BIO Technology Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd
07/07	Weight-loss drug developers line up to tap lucrative market as competition heats up
07/07	CSPC Pharma Begins Phase II Trial of Mixed Hyperlipidaemia Drug
07/07	CSPC Pharmaceutical Group Limited Initiates Phase II Clinical Trial Of SYH2070 Injection For Treatment Of Mixed Hyperlipidaemia At First Centre In China
02/07	European Stocks Surge, Oil Prices Drop; Defense, Luxury Shares Rally
02/07	CSPC Pharma Begins Tumor Drug Trial in China
02/07	AstraZeneca Collaborating With CSPC Pharma in siRNA Drug Deal Worth Up to $1.77 Billion
02/07	CSPC Pharma's Tumor Drug Gets Breakthrough Therapy Designation in China
02/07	CSPC Pharma Gets Marketing Nod for Anemia Drug in China
02/07	CSPC Pharma Gets China Nod for Trial of Herpes Zoster Vaccine
02/07	CSPC Pharma, AstraZeneca Enter Development Deal for Potential Renal Disease Drug Candidates
02/07	CSPC Pharmaceutical Group Limited Announces Iron Sucrose Injection Receives Marketing Approval
02/07	CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration for Recombinant Herpes Zoster Vaccine to Conduct Clinical Trial
02/07	CSPC Pharmaceutical Group Limited Officially Initiates Phase I Clinical Study of SYH2095 Tablets as Monotherapy or in Combination Regimens for the Treatment of Advanced Malignant Tumours in China